Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,894 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,867 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05504213 | A Phase Ib Study of HS-10352 Plus Fulvestrant in Patients With Advanced Breast Cancer | unknown | Phase 1 | 224 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 17, 2022 | clinicaltrials |
| NCT03934827 | MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the Tumour(MICROBIOME) | unknown | Phase 1 | 120 | Imperial College LondonOTHER | 1 | Aug 11, 2022 | clinicaltrials |
| NCT03805399 | FUSCC Refractory TNBC Umbrella (FUTURE)(FUTURE) | unknown | Phase 1 / Phase 2 | 140 | Fudan UniversityOTHER | 1 | Aug 10, 2022 | clinicaltrials |
| NCT04631835 | Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer | unknown | Phase 1 | 54 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 15, 2022 | clinicaltrials |
| NCT03788083 | Intratumoral TriMix Injections in Early Breast Cancer Patients(TMBA) | unknown | Phase 1 | 36 | Universitair Ziekenhuis BrusselOTHER | 1 | May 19, 2022 | clinicaltrials |
| NCT03913234 | Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients | unknown | Phase 1 / Phase 2 | 95 | Yonsei UniversityOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT05365204 | A Study for Optimization of 6% Hydroxyethyl Starch Based Indocyanine Green Near-infrared Fluorescence Navigated Sentinel Lymph Node Biopsy for Breast Cancer Patients | unknown | Phase 1 | 24 | National Taiwan University Hospital Hsin-Chu BranchOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT03251313 | PD-1(Programmed Death-1) Antibody +GP as First Line Treatment for Triple Negative Breast Cancer(TNBC) Patients | unknown | Phase 1 | 31 | Fudan UniversityOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT04609215 | ImmunoBreast - A Phase Ib Study | unknown | Phase 1 / Phase 2 | 20 | Henrik DitzelOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT05337657 | A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast Cancer | unknown | Phase 1 | 10 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | Apr 20, 2022 | clinicaltrials |
| NCT02637531 | A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 | unknown | Phase 1 | 219 | Infinity Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 4, 2022 | clinicaltrials |
| NCT04004910 | A Study Comparing Immunopheresis® Alone or In Combination With Chemotherapy Versus Chemotherapy Alone in Treatment of Advanced Breast Cancer Patients | unknown | Phase 1 / Phase 2 | 170 | Immunicom IncINDUSTRY | 2 | Mar 24, 2022 | clinicaltrials |
| NCT04669587 | ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study)(ENZENO) | unknown | Phase 1 / Phase 2 | 106 | EnhancedBio USA Inc.OTHER | 2 | Mar 22, 2022 | clinicaltrials |
| NCT05274893 | A Pharmacokinetic Comparison Study of SYHX2011 and Abraxane® in Patients With Advanced Breast Cancer | unknown | Phase 1 | 28 | CSPC Ouyi Pharmaceutical Co., Ltd.INDUSTRY | 0 | Mar 11, 2022 | clinicaltrials |
| NCT05273944 | Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection (Lipodox®) in Chinese Patients | unknown | Phase 1 | 80 | Shenzhen Kangzhe Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 10, 2022 | clinicaltrials |
| NCT05251766 | Nab-paclitaxel Compared With Docetaxel in the Neoadjuvant Chemotherapy Breast Cancer | unknown | Phase 1 | 30 | Xuli MengOTHER | 0 | Feb 23, 2022 | clinicaltrials |
| NCT02626507 | Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer | unknown | Phase 1 | 18 | Hoffman OncologyOTHER | 1 | Feb 9, 2022 | clinicaltrials |
| NCT02630368 | A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX)(METROmaJX) | unknown | Phase 1 / Phase 2 | 197 | Institut BergoniéOTHER | 1 | Feb 2, 2022 | clinicaltrials |
| NCT03847168 | KN026 in Patients With HER2 Expressing Breast Cancer and Gastric Cancer | unknown | Phase 1 | 22 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Nov 17, 2021 | clinicaltrials |
| NCT05103917 | A Study to Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBC | unknown | Phase 1 / Phase 2 | 24 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Nov 2, 2021 | clinicaltrials |
| NCT04061863 | Nivolumab and Eribulin in HER2 Negative Metastatic Breast Cancer(KORNELIA) | unknown | Phase 1 / Phase 2 | 90 | Seoul National University HospitalOTHER | 1 | Sep 8, 2021 | clinicaltrials |
| NCT04856371 | Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer | unknown | Phase 1 | 228 | Haihe Biopharma Co., Ltd.INDUSTRY | 0 | Apr 23, 2021 | clinicaltrials |
| NCT04170595 | Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody for Injection | unknown | Phase 1 / Phase 2 | 132 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | Mar 3, 2021 | clinicaltrials |
| NCT03749850 | Image-guided Targeted Doxorubicin Delivery With Hyperthermia to Optimize Loco-regional Control in Breast Cancer(i-GO) | unknown | Phase 1 | 12 | UMC UtrechtOTHER | 1 | Feb 17, 2021 | clinicaltrials |
| NCT04750382 | A Study of HX008 for the Treatment of Patients With Metastatic Triple Negative Breast Cancer | unknown | Phase 1 / Phase 2 | 31 | Taizhou Hanzhong biomedical co. LTDINDUSTRY | 1 | Feb 11, 2021 | clinicaltrials |
| NCT02500199 | Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors | unknown | Phase 1 | 50 | Hengrui Therapeutics, Inc.INDUSTRY | 1 | Feb 1, 2021 | clinicaltrials |
| NCT03125746 | A Study of LXI-15029 in Patients With Advanced Malignant Solid Tumors | unknown | Phase 1 | 72 | Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.INDUSTRY | 1 | Jan 5, 2021 | clinicaltrials |
| NCT04091958 | Reconstruction of Partial Mastectomy Defects With Pectoralis Myo-glandular Local Flap. | unknown | Phase 1 | 15 | Mansoura UniversityOTHER | 1 | Nov 19, 2020 | clinicaltrials |
| NCT04488107 | Safety, Tolerability, Pharmacokinetics and Antitumor Activity of FCN-437c | unknown | Phase 1 / Phase 2 | 78 | Ahon Pharmaceutical Co., Ltd.OTHER | 1 | Jul 27, 2020 | clinicaltrials |
| NCT04427215 | Complementary and Alternative Medicine on Mental Health in Breast Cancer Patients | unknown | Phase 1 | 250 | Klaipėda UniversityOTHER | 1 | Jun 11, 2020 | clinicaltrials |
| NCT04073680 | A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 60 | Petra PharmaINDUSTRY | 0 | May 21, 2020 | clinicaltrials |
| NCT02583542 | A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers(TORCMEK) | unknown | Phase 1 / Phase 2 | 118 | Queen Mary University of LondonOTHER | 1 | Feb 25, 2020 | clinicaltrials |
| NCT03994107 | Pegylated Liposomal Doxorubicin Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast Cancer | unknown | Phase 1 / Phase 2 | 40 | Peking Union Medical CollegeOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT04213898 | SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer | unknown | Phase 1 / Phase 2 | 39 | Henan Cancer HospitalOTHER_GOV | 0 | Dec 30, 2019 | clinicaltrials |
| NCT04152057 | Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast Cancer | unknown | Phase 1 / Phase 2 | 20 | West China HospitalOTHER | 1 | Nov 5, 2019 | clinicaltrials |
| NCT03855358 | A Study of TQB2450 Injection and Anlotinib Hydrochloride Capsules to Treat Triple Negative Breast Cancer (TNBC) | unknown | Phase 1 | 30 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Oct 30, 2019 | clinicaltrials |
| NCT04138342 | Topical Fluorescent Nanoparticles Conjugated Somatostatin Analog for Suppression and Bioimaging Breast Cancer | unknown | Phase 1 | 30 | Al-Azhar UniversityOTHER | 2 | Oct 24, 2019 | clinicaltrials |
| NCT04107142 | Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour | unknown | Phase 1 | 10 | CytoMed Therapeutics Pte LtdINDUSTRY | 1 | Sep 27, 2019 | clinicaltrials |
| NCT03881878 | TAHP for Patients With HER2-positive Early Breast Cancer and Subsequent AHP Adjuvant tHerapy After Surgery | unknown | Phase 1 / Phase 2 | 67 | Samsung Medical CenterOTHER | 1 | Mar 21, 2019 | clinicaltrials |
| NCT03518268 | Vivomixx for Prevention of Bone Loss in Women With Breast Cancer Treated With an Aromatase Inhibitor | unknown | Phase 1 / Phase 2 | 40 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 0 | Jan 17, 2019 | clinicaltrials |
| NCT02950064 | A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations | unknown | Phase 1 | 95 | Placon TherapeuticsINDUSTRY | 1 | Jan 14, 2019 | clinicaltrials |
| NCT03634501 | Clinical Study on Anti-tumor Effect Induced by Activated Primary Natural Killer（NK）Cells | unknown | Phase 1 / Phase 2 | 200 | Xuanwu Hospital, BeijingOTHER | 1 | Jan 11, 2019 | clinicaltrials |
| NCT02511301 | Circadian Thermal Sensing to Detect Breast Disease | unknown | Phase 1 / Phase 2 | 173 | Cyrcadia HealthINDUSTRY | 1 | Jan 3, 2019 | clinicaltrials |
| NCT03175341 | Intravenous Ascorbic Acid Supplementation in Neoadjuvant Chemotherapy for Breast Cancer | unknown | Phase 1 / Phase 2 | 30 | Academic Emergency County Hospital SibiuOTHER | 1 | Jun 27, 2018 | clinicaltrials |
| NCT03487055 | Safety Assessment of Repeated Administration of TK006 in Patients With Breast Cancer-related Bone Metastases | unknown | Phase 1 | 30 | Jiangsu T-Mab Biopharma Co.,LtdINDUSTRY | 0 | Apr 3, 2018 | clinicaltrials |
| NCT03076372 | A Study Evaluating MM-310 in Patients With Solid Tumors | unknown | Phase 1 | 34 | Merrimack PharmaceuticalsINDUSTRY | 1 | Feb 27, 2018 | clinicaltrials |
| NCT03442543 | Preoperative Localization of Sentinel Lymph Node in Breast Cancer Patients By Novel Computed Tomography-Lymphography Guided Technique | unknown | Phase 1 | 50 | Mansoura UniversityOTHER | 1 | Feb 23, 2018 | clinicaltrials |
| NCT03435666 | A Bioequivalence Study of Capecitabine Tablets 500 mg in Adult Cancer Patients Under Fed Condition(Capecitabine) | unknown | Phase 1 | 45 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Feb 19, 2018 | clinicaltrials |
| NCT03282825 | Clinical Study of Decitabine and Paclitaxel Combination Therapy | unknown | Phase 1 | 18 | Dong Wha Pharmaceutical Co. Ltd.INDUSTRY | 1 | Jan 23, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Aug 17, 2022source: clinicaltrials